Drug Profile
Tepilamide fumarate - Arbor Pharmaceuticals/Dr. Reddy's Laboratories
Alternative Names: Methyl hydrogen fumarate prodrug - Arbor Pharmaceuticals; PPC 06; XP-23829Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator XenoPort
- Developer Dr Reddys Laboratories; XenoPort
- Class Amides; Anti-inflammatories; Antipsoriatics; Esters; Fumarates; Small molecules
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Plaque psoriasis
- Discontinued Multiple sclerosis; Parkinson's disease
Most Recent Events
- 30 Nov 2022 No development reported - Phase-II for Plaque psoriasis in USA (PO) (NCT03421197)
- 30 Mar 2020 Dr. Reddy's Laboratories completes a phase II AFFIRM trial in Plaque psoriasis in USA (PO) (NCT03421197)
- 10 Jun 2019 Topline efficacy and adverse events data from the phase II AFFIRM trial in Plaque psoriasis released by Dr. Reddy's Laboratories